Global Gene Editing Market
Dublin, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Gene Editing Market by Product & Service (Reagents, Consumables, Systems, Software), Technology (CRISPR, TALEN, ZFN, Antisense), Application (Cell Line Engineering, Genetic Engineering, Drug Discovery), End User (Pharma, Biotech) - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
The gene editing market is on the brink of remarkable growth, projected to surge from USD 5.3 billion in 2023 to a whopping USD 10.6 billion by 2028, marking an impressive Compound Annual Growth Rate (CAGR) of 15.0%. This phenomenal growth is attributed to the escalating government funding and proliferation of genomics projects, which are poised to significantly impact the market.
Government Funding and Genomics Projects Propel Growth
March 2022 witnessed a substantial boost in gene editing research as the US National Institutes of Health (NIH) expanded funding with a USD 89 million allocation for new projects. Simultaneously, the European Union initiated the Horizon 2020 program, a significant financial resource dedicated to advancing genomics research and gene editing ventures. Additionally, global players like China, Japan, and South Korea have established robust national genomics programs, fueling the advancement of gene editing technologies.
Gene Editing Services Lead the Surge
Intriguingly, gene editing services are predicted to witness the highest growth during the forecast period. The gene editing market is segmented into reagents & consumables, software & systems, and services. Notably, gene editing services encompass sequencing services, data analysis, bioinformatics services, and more. Service providers also offer tailored sequencing services, amplifying the demand for genomic sequencing in biomedical applications, consequently spurring growth in the gene editing market.
Pharmaceutical & Biotech Companies Dominate
Pharmaceutical & biotechnology companies took the lead in the global gene editing market in 2022. This dominance is attributed to the burgeoning demand for gene editing in pharmaceutical applications, especially in pharmacogenomics. Biomarkers' growing significance has driven the adoption of genomic systems and services, as they find versatile applications in drug development. Moreover, biotech companies are proactively building genomic databases to innovate and develop new therapeutics.
Asia Pacific: A Gene Editing Powerhouse
The Asia Pacific (APAC) region emerges as the epicenter of gene editing growth, expected to exhibit the highest Compound Annual Growth Rate (CAGR) during the forecast period. The region's surge is powered by substantial research investments and increasing applications of gene synthesis for engineering cells and tissues of organisms. Amidst this growth, Japan is grappling with cancer as a leading cause of death, prompting government initiatives such as the Japan Regenerative Medicine Project and Japan Cancer Research Project. Collaborations between local organizations and global giants also contribute to this dynamic landscape.